Tuesday, July 9, 2024 12:00 PM ET - 1:00 PM ET Eytan M. Stein, MD and David Sallman, MD

Wednesday, July 10, 2024 12:00 PM ET - 1:00 PM ET Marion Subklewe, MD

Thursday, July 11, 2024 12:00 PM ET - 1:00 PM ET David Sallman, MD and Marion Subklewe, MD

Changing Standards and Evolving Strategies in AML Patients Unfit for Intensive Chemotherapy

• Current standard of care for AML: intensive chemotherapy
• The role of diagnosis and genetic testing in AML treatment decisions
• Current standard of care in AML patients unfit for intensive chemotherapy
• Strategies for assessing performance status: geriatric testing versus the “gut feeling”
• Treatment in an academic center versus the community setting

Target Audience

This activity is intended for hematologists/oncologists and other healthcare providers involved in the treatment of patients with AML.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Outline current standards of care for intensive chemotherapy in patients with AML
• Summarize current complexities and limitations in the current management of patients with AML who are unfit for intensive chemotherapy
• Identify disease and clinical factors specific for AML that render patients unsuitable for intensive chemotherapy
• Evaluate current approaches to the treatment of older, fit patients with AML and the evolving use of non-intensive therapies in this patient subgroup

Disclosure As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity. Faculty Disclosures Dr. Eytan Stein has relevant financial relationships related to formal advisory activities from and owns significant holdings in Abbvie, Inc., Agios, Inc., Astellas Pharma US, Inc., Auron Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation – a Bristol-Meyers Squibb Company, Genentech, Inc., Gilead, Janssen Pharmaceuticals, Inc., Syndax Pharmaceuticals and Syros Pharmaceuticals, Inc. Dr. David Sallman has relevant financial relationships related to formal advisory/consultant activities from Abbvie, Inc., Affimed GmbH, Astellas Pharma US, Inc., AvenCell Therapeutics, Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, Dark Blue Therapeutics, Foghorn Therapeutics, Gilead, Incyte Corporation, Intellia Therapeutics, Inc., Intellisphere LLC, Jasper Therapeutics, Inc., Kite Pharma, Inc. – a Gilead Company, Magenta Therapeutics, Molecular Partners AG, Nkarta, Inc., Novartis AG, PGEN Therapeutics, Inc., Orbital Therapeutics Inc., Rigel Pharmaceuticals, Inc., Shattucks Labs, Inc., Servier, Syndax Pharmaceuticals, Syros Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited and Zentalis Pharmaceuticals, Inc.; and has received research support from Aprea Therapeutics and Jazz Pharmaceuticals, Inc. Dr. Marion Subklewe has no relevant financial relationships to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices. Planning Committee Joan Meyer, RN, MHA, Executive Director, Sheri Sturgis, Strategy and Education Manager, and Jennifer Murphy, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients. Peer Reviewer Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients. Instructions for Participation and Credit There are no fees for participating in this activity. In order to receive credit, all participants must complete the post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity. CME, CNE, and CE Credit certificates will be emailed 4 weeks following receipt of completed requirements. If you have any questions regarding the content of this activity, please contact MediCom Worldwide, Inc. at 800-408-4242 or [email protected]